Madrigal Pharmaceuticals Inc 0JXI-GB:London Stock Exchange

RT Quote | Exchange | USD
Last | 2:56 PM BST
0.00UNCH (UNCH)
52 week range
122.87 - 316.00
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.00
  • 52 Week High316.00
  • 52 Week High Date03/15/24
  • 52 Week Low122.87
  • 52 Week Low Date10/26/23

Key Stats

  • Market Cap4,342.48M
  • Shares Out21.28M
  • 10 Day Average Volume777.2
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-2.01

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.00
  • 52 Week High316.00
  • 52 Week High Date03/15/24
  • 52 Week Low122.87
  • 52 Week Low Date10/26/23
  • Market Cap4,342.48M
  • Shares Out21.28M
  • 10 Day Average Volume777.2
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-2.01

RATIOS/PROFITABILITY

  • EPS (TTM)-19.93
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Madrigal Pharmaceuticals Inc

 

Profile

MORE
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes...
Julian Baker
Independent Chairman of the Board
Bill Sibold
President, Chief Executive Officer, Director
Mardi Dier
Chief Financial Officer, Senior Vice President
Ronald Filippo
Chief Information Officer
Address
200 Barr Harbor Dr Ste 400
West Conshohocken, PA
19428-2978
United States